Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish · 2018
DOI: 10.1177/2284240318790951 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018. Verfasst von Roberto Ravasio und 5 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ravasio, R., Antonelli, S., Rogai, V., Fakhouri, W., Capron, J. P., & Losi, S. (2018). Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. https://doi.org/10.1177/2284240318790951
Vancouver
Ravasio R, Antonelli S, Rogai V, Fakhouri W, Capron JP, Losi S. Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish. 2018. doi:10.1177/2284240318790951
BibTeX
@article{Ravasio2018,
author = {Ravasio, Roberto and Antonelli, Silvia and Rogai, Veronica and Fakhouri, Walid and Capron, Jean Philippe and Losi, Serena},
title = {Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy},
journal = {Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish},
year = {2018},
doi = {10.1177/2284240318790951}
}
EUVIMED